Overview

Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Status:
Active, not recruiting

Trial end date:
2021-12-22

Target enrollment:

Participant gender:

Summary

Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

Phase:

Phase 2

Details

Lead Sponsor:

Actelion

Treatments:

Macitentan